Voyager Therapeutics is in the biotechnology industry and is part of the healthcare sector. The company CEO is G. Andre Turenne. Voyager Therapeutics Inc in collaboration with Genzyme, conducts research and development work to develop therapies for the treatment of central nervous system disorders. It targets diseases such as Parkinson’s, Alzheimer’s Huntington’s.



Previous Intraday Performance:

The VYGR shares had a previous change of 4.46% which opened at 23.08 and closed at 22.85. It moved to an intraday high of 23.98 and a low of 23.00.

SeekingAlpha:  3 Gene Therapy Stocks For A Biotech Portfolio

Historical Performance:

Over the last five trading days, VYGR shares returned 3.16% and in the past 30 trading days it returned 6.83%. Over three months, it changed 64.86%. In one year it has changed 15.52% and within that year its 52 week high was 25.74 and its 52 week low was 7.76. VYGR stock is 194.46% above its 52 week low.

Our calculations result in a 200 day moving average of 15.93 and a 50 day moving average of 21.04. Right now, VYGR stock is trading 43.42% above its 200 day moving average.

SeekingAlpha:  3 Gene Therapy Stocks For A Biotech Portfolio

Liquidity:

The company has a market cap of $879.2m with 36.8m shares outstanding and a float of 35.4m shares. Trading volume was 163,605 shares and has experienced an average volume of 387,182 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Voyager Therapeutics was -2.75 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.71.

1stQtr 2019 -0.814thQtr 2018 -0.703rdQtr 2018 -0.632ndQtr 2018 -0.801stQtr 2018 -0.63

The next earnings report will be: 05-28-2019

Base on our calculations, the intrinsic value per share is 44.60, which means it might be undervalued and has a margin of safety of 48.76%.

The growth of the EPS is critical in understanding the current valuation of Voyager Therapeutics; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 8.70% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 96.70% of institutional ownership.

The beta was calculated to be 2.61.

Business Wire:  Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -100.44%, return on assets is -30.55%, price-to-sales is 70.88 and price-to-book is 8.36.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here